Publications and Presentations

Check out our publications and poster presentations.

January 2017

Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer

Cell Reports

December 2016

Phase I study of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with triple negative breast cancer

San Antonio Breast Cancer Symposium

November 2016

Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase, In Combination with Everolimus in Patients with Clear Cell and Papillary Renal Cell Carcinoma CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors

NCI AACR EORTC – 2016

November 2016

Arginase inhibitor CB-1158 elicits immune-mediated anti-tumor responses as a single agent and enhances the efficacy of other immunotherapies

NCI AACR EORTC – 2016

November 2016

Arginase Inhibitor CB-1158 Alleviates Immunosuppression And Enhances Anti-Tumor Responses As A Single Agent And In Combination With Other Immunotherapies CX-1158-101: A First-in-Human Phase 1 Study of a Small Molecule Inhibitor of Arginase (CB-1158) as Monotherapy and in Combination with an anti-PD-1 Checkpoint Inhibitor in Patients with Solid Tumors

Society for Immunotherapy of Cancer

Our Pipeline

We are focused on solid tumors for
which new treatments are urgently needed.

View Our Pipeline